These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 22118347)

  • 1. Influences of neuroregulatory factors on the development of lower urinary tract symptoms/benign prostatic hyperplasia and erectile dysfunction in aging men.
    Mazur DJ; Helfand BT; McVary KT
    Urol Clin North Am; 2012 Feb; 39(1):77-88. PubMed ID: 22118347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia.
    Gacci M; Eardley I; Giuliano F; Hatzichristou D; Kaplan SA; Maggi M; McVary KT; Mirone V; Porst H; Roehrborn CG
    Eur Urol; 2011 Oct; 60(4):809-25. PubMed ID: 21726934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of phosphodiesterase type 5 inhibitors for lower urinary tract symptoms.
    Miller MS
    Ann Pharmacother; 2013 Feb; 47(2):278-83. PubMed ID: 23386068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct effects of tadalafil on lower urinary tract symptoms versus indirect effects mediated through erectile dysfunction symptom improvement: integrated data analyses from 4 placebo controlled clinical studies.
    Brock GB; McVary KT; Roehrborn CG; Watts S; Ni X; Viktrup L; Wong DG; Donatucci C
    J Urol; 2014 Feb; 191(2):405-11. PubMed ID: 24096120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erectile dysfunction diagnosis and treatment as a means to improve medication adherence and optimize comorbidity management.
    Scranton RE; Goldstein I; Stecher VJ
    J Sex Med; 2013 Feb; 10(2):551-61. PubMed ID: 23153075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new experimental rat model of erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: the testosterone-supplemented spontaneously hypertensive rat.
    Oudot A; Oger S; Behr-Roussel D; Caisey S; Bernabé J; Alexandre L; Giuliano F
    BJU Int; 2012 Nov; 110(9):1352-8. PubMed ID: 22448674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alpha-adrenoceptors are a common denominator in the pathophysiology of erectile function and BPH/LUTS--implications for clinical practice.
    Yassin A; Saad F; Hoesl CE; Traish AM; Hammadeh M; Shabsigh R
    Andrologia; 2006 Feb; 38(1):1-12. PubMed ID: 16420236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Sexual dysfunctions linked with prostatic diseases].
    Rouprêt M; Seisen T; De La Taille A; Desgrandchamps F
    Prog Urol; 2012 Jun; 22 Suppl 1():S14-20. PubMed ID: 22770495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lower urinary tract symptoms (LUTS) and sexual dysfunction (SD): new targets for new combination therapies?
    Sciarra A
    Eur Urol; 2007 Jun; 51(6):1485-7. PubMed ID: 17275984
    [No Abstract]   [Full Text] [Related]  

  • 10. Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia in men with or without erectile dysfunction.
    Broderick GA; Brock GB; Roehrborn CG; Watts SD; Elion-Mboussa A; Viktrup L
    Urology; 2010 Jun; 75(6):1452-8. PubMed ID: 20163842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms.
    Tinel H; Stelte-Ludwig B; Hütter J; Sandner P
    BJU Int; 2006 Dec; 98(6):1259-63. PubMed ID: 16956354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of phosphodiesterase-5 inhibitors and alpha-blockers in patients with benign prostatic hyperplasia: treatments of lower urinary tract symptoms, erectile dysfunction, or both?
    Carson CC
    BJU Int; 2006 Apr; 97 Suppl 2():39-43; discussion 44-5. PubMed ID: 16507053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The positive effect of sildenafil on LUTS from BPH while treating ED].
    Ying J; Yao D; Jiang Y; Ren X; Xu M
    Zhonghua Nan Ke Xue; 2004 Sep; 10(9):681-3. PubMed ID: 15497711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is there a rationale for the chronic use of phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia?
    Roumeguère T; Zouaoui Boudjeltia K; Hauzeur C; Schulman C; Vanhaeverbeek M; Wespes E
    BJU Int; 2009 Aug; 104(4):511-7. PubMed ID: 19239452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of metabolic syndrome on erectile dysfunction and lower urinary tract symptoms in benign prostatic hyperplasia patients.
    Aktas BK; Gokkaya CS; Bulut S; Dinek M; Ozden C; Memis A
    Aging Male; 2011 Mar; 14(1):48-52. PubMed ID: 21087172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between erectile dysfunction and lower urinary tract symptoms due to benign prostatic hyperplasia in Nigerian men.
    Ikuerowo SO; Akindiji YO; Akinoso OA; Akinlusi FM; Esho JO
    Urol Int; 2008; 80(3):296-9. PubMed ID: 18480635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of once-daily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasia.
    Porst H; McVary KT; Montorsi F; Sutherland P; Elion-Mboussa A; Wolka AM; Viktrup L
    Eur Urol; 2009 Oct; 56(4):727-35. PubMed ID: 19409693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging.male (MSAM-7)].
    Rosen R; Altwein J; Boyle P; Kirby RS; Lukacs B; Meuleman E; O'Leary MP; Puppo P; Chris R; Giuliano F
    Prog Urol; 2004 Jun; 14(3):332-44. PubMed ID: 15373175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Phosphodiesterase inhibitors: effectiveness and new applications].
    van Driel MF
    Ned Tijdschr Geneeskd; 2006 Jul; 150(29):1613-6. PubMed ID: 16901064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction.
    Kaplan SA; Gonzalez RR; Te AE
    Eur Urol; 2007 Jun; 51(6):1717-23. PubMed ID: 17258855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.